India’s 55th GST Council meeting, chaired by Union Finance Minister Nirmala Sitharaman, announced a complete exemption of Goods and Services ...
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases...
A2A Pharmaceuticals, Inc. ("A2A" or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies...
Microbio Co., Ltd. (4128) revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage II...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programs for vibostolima...
Jaypirca®, a highly selective kinase inhibitor, utilizes a novel non-covalent binding mechanism to re-establish BTK inhibition in mantle cell lymphoma ...
Accropeutics Inc. (Accropeutics), a clinical-stage biotech company with a focus on molecular mechanisms of regulated cell death and related pathogenesis in...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., shared new data ...
Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen recept...
In a compelling conversation with BioPharma BoardRoom, Venkata Indurthi, Chief Scientific Officer at Aldevron, shares insights into the inn...
In a thought-provoking Q&A with BioPharma BoardRoom, Demaris Mills, President of Integrated DNA Technologies (IDT), discusses the transformative advanc...
In a detailed interview with BioPharma BoardRoom, Kerstin Pohl, Senior Global Marketing Manager for Gene Therapy & Nucleic Acid at SCIEX, delves into t...
Roche (SIX: RO, ROG; OTCQX: RHHBY) that new and updated data from its industry-leading CD20xCD3 T-cell-engaging bispecific antibody programme were presente...
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdege...
© 2025 Biopharma Boardroom. All Rights Reserved.
